U.S. FDA Approves Expanded Indication for Gilead ’s Biktarvy to Treat People with HIV with Suppressed Viral Loads, Pre-Existing Resistance

FOSTER CITY, Calif.--(BUSINESS WIRE) February 26, 2024 -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) approved a new, expanded indication for Biktarvy® (bictegravir 50 mg/emtricitabine 200...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news